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Abstract
This study investigates the role of basolateral amygdala (BLA) dopamine in heroin-induced
conditioned immunomodulation. Animals underwent conditioning in which heroin administration
was repeatedly paired with placement into a conditioning chamber. Six days after the final
conditioning session animals were returned to the chamber and received intra-BLA microinfusions
of dopamine, D1 or D2, antagonist. Antagonism of D1, but not D2, receptors within the BLA
blocked the suppressive effect of heroin-associated environmental stimuli on iNOS, TNF-α and
IL-1β. This study is the first to demonstrate that the expression of heroin’s conditioned effects on
proinflammatory mediators require dopamine D1 receptors within the BLA.
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1. Introduction
The high rate at which heroin users contract opportunistic infections suggests that heroin use
may impair the ability of the host to combat infectious disease (Luttgens, 1949; Hussey &
Katz, 1950; Louria et al., 1967). Although it has been postulated that this high rate of
infection amongst heroin users results from increased contact with pathogens, possibly
through needle sharing or impurities in street grade drugs, there is evidence that heroin may
directly impact the clinical course of infection (Kreek, 1990; Farizio et al., 1992; McLachlan
et al., 1993) and diseases associated with intravenous heroin use may be influenced by the
ability of opioids to modulate immune function (McDonough et al., 1980; Donahoe et al.,
1986; Novick et al., 1989; Ochshorn et al., 1990). In fact, clinical studies report
abnormalities in basic immune parameters in heroin users, including decreased numbers of
circulating lymphocytes, decreased NK cell activity, and reduced antibody-dependent
cellular cytotoxicity (Nair et al., 1986; Govitrapong et al., 1998), suggesting that heroin may
further contribute to increased infection susceptibility among users, independently of
concurrent risk factors. In further support of this, studies have indicated that human heroin
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users exhibit poorer immune responses following hepatitis vaccination (Quaglio et al. 2004;
Rodrigo et al., 1992).
New studies in our laboratory have indicated that heroin induces alterations in a number of
immunological parameters including alterations in natural killer cell activity, T- and B-
lymphocyte proliferation, and nitric oxide production (Fecho et al. 2000; Lysle & How
2000). Nitric oxide is produced by many cells of the immune system and it mediates diverse
biological functions including vasodilation, the cytotoxic activity of macrophages, and the
inhibition of platelet adhesion and aggregation (Suschek et al., 2004; Tuteja et al., 2004).
Opiate drug administration has also been found to alter the production of several
proinflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-
one beta (IL-1β) (Chao et al 1993; Bencsics et al 1997; Pacifici et al 2000; Clark et al.,
2007). IL-1β and TNF-α both play critical roles in the body’s defense against infectious
challenge, while also serving to regulate the immune response to these challenges.
Previous research has shown that the effects of heroin on proinflammatory mediators (nitric
oxide, IL-1β and TNF-α) may be conditioned to environmental stimuli that have been
associated with drug administration (e.g., Lysle & Ijames, 2002; Szczytkowski & Lysle,
2007) and that these conditioned effects are attenuated by inhibition of the basolateral
amygdala (Szczytkowski & Lysle, 2008). These findings suggest that the basolateral
amygdala is an integral component of the circuit mediating the conditioned effects of heroin
on proinflammatory mediators. The current study further explores the role of basolateral
amygdala by examining the dopaminergic inputs to this brain region and their involvement
in the expression of heroin-induced conditioned immunomodulation. Interestingly, the
dopaminergic system within the BLA has been shown to be involved in learning and
memory and specifically the associative learning that underlies classical conditioning. For
example, intra-amygdalar 6-hydroxydopamine injections impaired (Ashford & Jones, 1976),
while post-training intra-BLA dopamine infusions enhanced (LaLumiere et al., 2004)
memory consolidation of a conditioned avoidance task. In addition, rats with 6-
hydroxydopamine lesions of the amygdala exhibit impaired acquisition of conditioning to
explicit cues (Selden et al., 1991). Microdialysis studies revealed an increase in dopamine
and its metabolites during the learning of a discriminative task in rats (Hori et al., 1993)
further supporting the importance of this neurotransmitter in BLA-mediated learning and
memory. Furthermore,Macedo et al. (2007) demonstrated that antagonism of dopamine D1
receptors within the BLA reduces the expression of conditioned, but not unconditioned, fear.
Dopaminergic signaling within the BLA appears to be particularly important for the
associative learning processes that accompany the acquisition and expression of conditioned
responses to drugs of abuse. For example, intra-BLA administration of D-amphetamine
potentiates cue-induced cocaine seeking possibly by increasing monoamine tone in this
region (Ledford et al., 2003). In addition, site specific adminstration of a dopamine D1/D2/
D3 antagonist into the basolateral amygdala, but not the central amygdala, blocks alcohol-
induced conditioned place preference in mice (Gremel & Cunningham, 2008). More
specifically, stimulation of dopamine D1 receptors in the BLA was found to be necessary for
the expression of cue-induced reinstatement of cocaine-seeking behavior in rats (See et al.,
2001; Yun & Fields, 2003). In contrast, dopamine D2 receptors in the BLA appear to be
involved in the acquisition of associations between drugs of abuse and the conditioned cues
that guide subsequent cue-induced drug-seeking behavior (Berglind et al., 2006). These
findings provide a strong rationale for examining the involvement of the dopaminergic
system within the BLA on the expression of heroin-conditioned immunomodulation.
The current set of experiments sought to establish the role of the dopaminergic system
within the basolateral amygdala in the conditioned effects of heroin on proinflammatory
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mediators. Rats received five training sessions in which heroin was administered
immediately upon placement into a standard conditioning chamber which served as the
conditioned stimulus (CS). On the test day, the animals were re-exposed to the chamber for
60-min without drug administration and given a subcutaneous injection of LPS (1000 µg/kg)
upon removal. Immediately prior to CS reexposure, animals received intra-BLA infusion of
either saline vehicle, SCH23390 (dopamine D1 receptor antagonist) or raclopride (D2
antagonist) to determine the role of dopamine signaling in heroin-induced conditioned
immunomodulation. The findings reported here are important because they indicate that
previously heroin-associated environmental stimuli are not only capable of inducing
alterations in proinflammatory mediators but that these effects may be modified by
antagonism of specific dopaminergic receptors within the BLA.
2. Materials and Methods
Animals
Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories
(Raleigh, N.C., USA). Upon arrival, animals were housed individually in plastic cages in a
colony room with a reversed light-dark (12h) cycle maintained through artificial
illumination. Animals were allowed access to food and water ad libitum throughout the
experiment except for the time spent in the conditioning chambers when food and water
were not available. All animals were given a 2-week habituation period before the start of
experimental manipulations and were handled regularly during this time. All procedures
described were approved by the IACUC of the University of North Carolina at Chapel Hill
and conformed to National Institutes of Health (NIH) Guidelines on the Care and Use of
Laboratory Animals.
Drug Administration
Heroin (diacetylmorphine) was obtained from NIDA (Bethesda, MD) and dissolved in 0.9 %
sterile saline. For all experiments, animals received a subcutaneous injection of heroin at a
dose 1 mg/kg immediately prior to placement in the conditioning chamber on each of the
five conditioning trial days. This dose was selected based on prior experiments in our
laboratory showing that a 1 mg/kg dose of heroin alters LPS-induced iNOS, IL-1β and TNF-
α mRNA expression in spleen and liver tissue and induces conditioning (Lysle & How,
2000; Lysle & Ijames, 2002; Szczytkowski & Lysle, 2007).
Surgery and microinjection
Animals were anesthetized with 0.35 ml intramuscular injections of 1:1 (vol/vol) ketamine
hydrochloride (100 mg/ml) mixed with xylazine (20 mg/ml) and placed into the stereotaxic
apparatus. Animals were implanted with 26-gauge bilateral guide cannula (Plastics One,
Roanoke, VA) directed towards the BLA (AP −2.5, ML±5.0, DV −6.6). Coordinates are
expressed as millimeters from bregma (Paxinos & Watson, 1986). Animals were given a two
week recovery period before the start of conditioning trials. On test day, animals received
bilateral intracranial injections (0.5 µl/side infused over 1 min) of saline vehicle, the D1
antagonist, SCH23390 (2 µg/0.5 µl/side) or the D2 antagonist, raclopride (5 µg/0.5 µl/side)
30 minutes prior to re-exposure to the conditioning chambers. Antagonist doses were chosen
based upon previous behavioral studies that had shown reductions in cue-induced drug
seeking following administration of these doses into the BLA (Berglind et al, 2006; See et
al, 2001). Injectors extended 2 mm beyond the tip of the cannula and were left in place for 1
minute after the injection to allow for proper infusion.
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To confirm proper cannula placement Alcian blue dye was infused via the cannula following
sacrifice. Brains were then extracted and post-fixed in a 4% paraformaldehyde solution.
Following fixation the brains were transferred to a 30% sucrose solution for cryoprotection
and then frozen at −80° C until further analysis. Coronal sections (50 µm) were taken and
stained with cresyl violet for verification of cannula placement. Animals with cannula
placement outside of the targeted region were removed from the analyses.
Procedures
Acquisition of conditioned response—To condition heroin’s effects on iNOS
expression, all animals received five 60-min training sessions in which they received a
subcutaneous injection of heroin upon placement into a standard conditioning chamber.
Training sessions were separated by 48 h. The conditioning chambers (BRS/LVE, Laurel,
MD, USA) were contained in a room separate from the animal colony and contained a metal
grid floor design and cedar bedding to create an environment distinct from that of the home
cage. All conditioning took place during the dark phase of the light cycle, and the
conditioning chambers were kept dark.
Testing of expression of conditioned response—The test day took place six days
following the final conditioning session. To test the expression of the conditioned response,
animals were re-exposed to the conditioned stimulus (i.e.; the conditioning chambers)
without drug to determine whether the conditioned stimulus alone would induce alterations
in pro-inflammatory mediators. Thirty minutes prior to testing, animals received intra-BLA
microinfusions of either the D1 antagonist, SCH23390, or the D2 antagonist, raclopride.
Control animals received intra-BLA microinfusions of saline vehicle. Two groups of
animals were then re-exposed to the chambers (conditioned stimulus, CS) for 60-min
without further administration of heroin. The remaining animals (home cage, HC) were
returned to the home cage following microinfusions and served as controls. After the 60-min
re-exposure, the animals were removed from the chambers and given a subcutaneous
injection of LPS (1000 µg/kg) to induce iNOS, TNF-α and IL-1β production. Home cage
animals also received LPS at this time. Six hours after LPS administration all animals were
sacrificed and samples of spleen, liver and blood were collected for analysis. Spleen and
liver tissue were collected as immunohistochemical localization of iNOS in rats exposed to
LPS has shown the presence of the iNOS enzyme in a number of immune cells in a variety
of tissues including eosinophils within the spleen and Kupffer’s cells and hepatocytes within
the liver (Bandaletova et al., 1993). The 6-hr timepoint was selected based on previous
research in our laboratory showing maximal iNOS induction at six hours following LPS
administration (Lysle & How, 2000).
Real Time RT-PCR
To determine iNOS expression, real time RT-PCR was performed on tissue samples from
the spleen and liver. Total RNA was extracted from a section of each of the tissues using
TRI-Reagent (Molecular Research Center, Cincinnati, OH), a modification of the original
method described by Chomczynski and Sacchi (1987). RNA was quantified
spectrophotometrically (GeneQuant II, Pharmacia-Biotech, Piscataway, NJ, USA). For the
RT-PCR, reverse transcription is performed using Oligo(dT)18 primer and Moloney Murine
Leukemia Virus-Reverse transcriptase following the protocol of the Advantage RT-for-PCR
Kit from Clontech (Palo Alto, CA, USA).
PCR amplifications were performed using the Fast Start™ DNA Master SYBR Green I
Real-Time PCR Kit (Roche) and the LightCycler instrument (Roche). A master mix
containing all reaction components was prepared for all reactions, with each reaction using a
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20 ml mix placed in glass capillary tubes specifically designed for use in the LightCycler
system. The PCR primer set for iNOS, 5’-CCCTTCCGAAGTTTCTGGCAGCAGC-3’ and
5’-GGGTGTCAGAGTCTTGTGCCTTTGG-3’ was synthesized by the Nucleic Acids Core
Facility (Lineberger Cancer Center, UNC-Chapel Hill). Copy numbers were generated from
an external standard curve. Amplifications were carried out for 40 cycles and curves
showing fluorescence at each cycle were determined by the computer software (Roche).
Samples were pre-incubated for 10 minutes at 95° C to activate the Fast-Start Taq DNA
polymerase. The cycle temperatures were 95, 60, and 72°C for the denaturing, annealing,
and extending, respectively. The cycle times were 15, 5, and 25 s for the denaturing,
annealing, and extending, respectively. Flourescence level was determined at the end of the
extending phase for each cycle of PCR. The analysis of the fluorescence level in standards
and samples over the course of 40 cycles was used to derive the number of copies of the
target molecule in each sample. Additionally, assessments of housekeeping gene expression,
cyclophilin, were made to assure comparable quality of RNA among samples. The sequence
of the cyclophilin primers was 5’-CCAAGACTGAGTGGCT-3’ and 5’-
AGATTACAGGGTATTGCG-3’. The data are expressed as a copy number of iNOS (per
10ng cDNA) based on the standard curve using the Lightcycler software (Roche).
Furthermore, to confirm the nature of amplification product, a melt curve analysis was
conducted after the final PCR cycle. This analysis involved denaturing the products by
slowly heating them to 95°C, during which fluorescence is continuously measured.
ELISA
For IL-1β and TNF-α protein determinations, protein was extracted from a section of each
homogenized tissue using freeze/thaw lysis in tris-buffer containing antiproteinases. Protein
was quantified spectrophotometrically (Bio-Tek, Model EL312 kinetic reader, Winooski,
VT, USA) using Bio-Rad protein dye. To account for variability in tissue size, samples were
normalized per unit protein based on the results of the spectrophotometric analysis. The
BioSource International, Inc. (Carlsbad, CA) rat IL-1β and TNF-α ELISA test kits were
used to determine the levels of IL-1β or TNF-α protein in each tissue sample. Briefly,
samples and standards were added to microtiter wells coated with antibody that recognizes
IL-1β or TNF-α and incubated at room temperature. Wells were washed extensively and
then incubated with biotinylated antibody, followed by a second wash and then incubation
with Streptavidin-HRP. After the final washing, a chromagen substrate solution was added
which reacted with the bound enzyme to produce color. The color intensity developed
proportionally to the amount of IL-1β or TNF-α present in each sample. The enzyme
reaction was stopped after 30 minutes, and the absorbance at 450 nm was measured with a
Bio-Tek (Winooski, VT) Model EL312 kinetic reader. A standard curve was obtained by
plotting the absorbance versus the corresponding concentrations of the supplied standards.
Nitrite/Nitrate Assay
The level of nitrite/nitrate in plasma samples was assessed using the Greiss reagent assay.
Nitrate and nitrite are formed non-enzymatically when nitric oxide is exposed to oxygen,
thus plasma levels of these products indicate the level of nitric oxide production. Total
nitrite/nitrate levels is determined by the conversion of nitrate to nitrite utilizing nitrate
reductase in the presence of NADPH and flavin adenine dinucleotide, and then an
assessment using Greiss reagent. Briefly, 6 µl of plasma diluted in 44 µl of dH2O is
incubated for in the dark for 90-min with 10 µl of nitrate reductase (1.0 unit/ml), 20 µl of a
0.31 M phosphate buffer (ph 7.5), 10 µl of 0.86 mM NADPH (Sigma), and 10 µl of a 0.11
mM flavin adenine dinucleotide in individual wells of a 96-well plate. Then, 200 ml of
Griess reagent consisting of a 1:1 (v/v) solution 1% sulfanilamide in 5.0% phosphoric acid
and 0.1% N-(1-napthyl)ethyl-enedamine dihydrochloride in distilled water was added to the
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samples. The color developed for ten minutes at room temperature after which the
absorbance was determined using a spectrophotometer set at 550 nm. All reactions were
carried out in triplicate. The total micromolar concentration of nitrite is determined for each
sample based on a standard curve. Recovery of nitrate is greater than 95% using this assay.
Statistical Analysis
Analysis of variance was performed on all data sets. When the overall ANOVA showed
significant effects, post hoc comparisons were made using Tukey’s test to compare
individual treatment groups to the home cage control. All analyses were conducted with the
level of significance set at p < 0.05.
3. Results
D1 Receptor Antagonism
The first study investigated the effect of intra-BLA microinfusion of the D1 receptor
antagonist, SCH23390, on the expression of heroin-induced conditioned suppression of
proinflammatory mediators. Six days following the final conditioning session, animals were
divided into groups with one group being re-exposed to the previously heroin-paired
environment for 60 min (CS Exposed) while the control groups remained in the home cage.
In order to temporarily block the receptors under investigation, animals in the SCH23390
groups received microinfusions of the SCH23390 compound directly into the BLA 30
minutes prior to testing of the conditioned response. The animals in the saline-treated groups
received microinfusions of saline into the BLA.
Figure 1 shows the mean levels of LPS-induced iNOS mRNA expresssion in the spleen and
liver for each group of animals. Analysis of iNOS copy number in spleen and liver,
respectively, revealed a significant main effect of group [F(3,15)=9.885, P<0.01;
F(3,15)=16.883, p<0.01]. Moreover, post-hoc analyses revealed a significant difference in
iNOS mRNA copy number between the saline-treated animals exposed to the conditioned
stimulus on test day (Saline, white bar) and the animals who remained in the home cage on
test day (Saline, black bar). These differences were evident in both tissues (p<0.05) which
reconfirms our earlier findings indicating that exposure to a previously heroin-paired
environment suppresses the expression of iNOS mRNA. Most importantly, there were no
significant differences between the saline-treated control group (Saline, black bar) and the
SCH23390-treated CS-exposed group (SCH23390, white bar) for either tissue. These results
demonstrate that antagonism of dopamine D1 receptors in the BLA blocks the conditioned
effects of a previously heroin-paired environment on iNOS mRNA expression.
The data in Figure 2 show levels of serum nitrite/nitrate levels for each group. The ANOVA
revealed a significant main effect of procedure [F(3,15) = 10.789, P<0.01] on the levels of
nitrite/nitrate in the serum. Post-hoc analyses revealed a significant difference between the
saline-treated animals exposed to the conditioned stimulus on test day (Saline, white bars)
and the animals who remained in the home cage on test day (Saline, black bars) (p<0.05).
These results further support our earlier findings that exposure to a previously heroin-paired
environment decreases serum nitrite/nitrate levels, indicating a reduction in nitric oxide
production. There were no significant differences between the SCH23390-treated group
exposed to the conditioned stimulus on test day (SCH23390, white bar) and the saline-
treated control group (Saline, black bar) indicating that the antagonism of dopamine D1
receptors in the BLA attenuated the conditioned response. There were also no differences
between the saline-treated control group (Saline, black bar) and the SCH23390-treated
control group (SCH23390, black bar) indicating that administration of SCH23390 alone
does not alter nitrate levels in the serum.
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Figure 3 illustrates that the suppressive effect of heroin on mRNA and protein levels of the
pro-inflammatory cytokine, IL-1β, can be conditioned to environmental stimuli and this
conditioned effect may be reduced by antagonism of dopamine D1 receptors within the
BLA. Analysis revealed a significant main effect of treatment on mRNA levels in the spleen
[F(3,15)=6.794, p<0.01] and liver [F(3,15)=8.929, p<0.01] as well as a main effect of
treatment on protein levels in the spleen [F(3,15)=7.873, p<0.01] and liver [F(3,15)= 3.694,
p<0.05]. In line with our previous experiments, the saline-treated conditioned group exposed
to the CS (Saline, white bar) exhibited significantly lower levels of IL-1β mRNA and
protein in both the spleen and liver (p<0.05) as compared to the saline-treated home cage
control group (Saline, black bar). Most importantly, the SCH23390-treated CS-exposed
group (SCH23390, white bar) was not significantly different from the saline-treated home
cage control group (Saline, black bar) for either tissue indicating that inactivation of the
BLA was able to attenuate the conditioned effects of heroin on IL-1β. There were also no
significant differences between the SCH23390-treated control group and the saline-treated
control group indicating that SCH23390-treatment alone did not have an effect on IL-1β
mRNA or protein levels in the spleen or liver.
Figure 4 shows that the suppressive effect of heroin on the proinflammatory cytokine, TNF-
α, may be conditioned to environmental stimuli and, again, this conditioned effect is
reduced by antagonism of dopamine D1 receptors within the BLA. This effect was evident at
the mRNA and protein level in both spleen and liver tissue. Analysis revealed a main effect
of treatment on mRNA and protein, respectively, in both spleen [F(3,15)=6.415, p<0.01;
F(3,15)=9.027, p<0.01] and liver [F(3,15)=7.313, p<0.01; F(3,15)=9.996, p<0.01]. In line
with our previous experiments, the saline-treated group exposed to the conditioned stimulus
on test day exhibited significantly lower levels of TNF-α mRNA and protein in the spleen
and liver (p<0.05) when compared to the saline-treated home cage control group. In
addition, there were no significant differences between the saline-treated home cage control
group and either of the SCH23390-treated groups.
D2 Receptor Antagonism
The second study investigated the effect of intra-BLA microinfusion of the D2 receptor
antagonist, raclopride, on the expression of heroin-induced conditioned suppression of
proinflammatory mediators. The experimental design followed that of the D1 receptor
antagonist study with one group being re-exposed to the previously heroin-paired
environment for 60 min on test day while the control groups remained in the home cage. In
order to temporarily block the dopamine D2 receptors within the BLA, animals in the
raclopride-treated groups received microinfusions of the D2 antagonist directly into the BLA
30 minutes prior to testing of the conditioned response. The animals in the saline-treated
groups received microinfusions of saline into the same area.
Figure 5 shows the mean levels of LPS-induced iNOS mRNA expresssion in the spleen and
liver for each group of animals. Analysis of iNOS copy number in spleen and liver,
respectively, revealed a significant main effect of group [F(3,15)=7.173, P<0.01;
F(3,15)=7.816, p<0.01]. Moreover, post-hoc analyses revealed a significant difference in
iNOS mRNA copy number between the saline-treated animals exposed to the conditioned
stimulus on test day (Saline, white bars) and the animals who remained in the home cage on
test day (Saline, black bars). These differences were evident in both tissues (p<0.05) which
reconfirms our earlier findings indicating that exposure to a previously heroin-paired
environment suppresses the expression of iNOS mRNA. Interestingly, there was also a
significant difference between the saline-treated home cage control group (Saline, black
bars) and the raclopride-treated CS-exposed group (Raclopride, white bars) for both tissues.
These results indicate that antagonism of dopamine D2 receptors in the BLA does not alter
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the conditioned effects of a previously heroin-paired environment on iNOS mRNA
expression.
The data in Figure 6 show the mean levels of serum nitrite/nitrate for each experimental
group. The ANOVA revealed a significant main effect of procedure [F(4,15) = 8.295,
P<0.05] on serum levels of nitrite/nitrate. Post-hoc analyses revealed a significant difference
between the saline-treated animals exposed to the conditioned stimulus on test day (Saline,
white bar) and the animals who remained in the home cage (Saline, black bar) (p<0.05).
These results are in line with our earlier experiments demonstrating that the suppressive
effect of heroin on serum nitrite/nitrate levels may be conditioned to environmental stimuli.
There was also a significant difference between the raclopride-treated group exposed to the
conditioned stimulus on test day (Raclopride, white bar) and the saline-treated home cage
control group (Saline, black bar) indicating that antagonism of dopamine D2 receptors
within the BLA does not have an effect on the conditioned response to a previously heroin-
paired environment.
Figure 7 shows that the suppressive effect of heroin on mRNA and protein levels of the pro-
inflammatory cytokine, IL-1β, can be conditioned to environmental stimuli and this
conditioned response is not altered by antagonism of dopamine D2 receptors within the
BLA. Analysis revealed a main effect of treatment on IL-1β mRNA levels in the spleen
[F(3,15)=18.94, p<0.01] and liver [F(3,15)=5.601, p<0.05] as well as protein levels in the
spleen [F(3,15)=34.440, p<0.01] and liver [F(3,15)=50.416, p<0.01]. In line with our
previous experiments, the saline-treated CS-exposed group exhibited significantly lower
levels of IL-1β mRNA and protein in the spleen and liver (p<0.05) as compared to the
saline-treated home cage control group. Most importantly, the raclopride-treated CS-
exposed group (Raclopride, white bars) also displayed signicantly lower levels of IL-1β
mRNA in the spleen and liver as compared to the saline-treated home cage control group
(Saline, black bars). These data suggest that antagonism of doapmine D2 receptors within
the BLA does not alter the conditioned effects of heroin on IL-1β mRNA levels. There were
also no significant differences between the raclopride-treated home cage control group and
the saline-treated home cage control group indicating that raclopride-treatment alone did not
have an effect on IL-1β mRNA or protein levels in the spleen or liver.
Figure 8 shows that the heroin-induced conditioned suppression of the proinflammatory
cytokine, TNF-α, is not affected by antagonism of dopamine D2 receptors within the BLA.
Analysis revealed a main effect of treatment on mRNA and protein in the spleen
[F(3,15)=10.23, p<0.01; F(3,15)=6.567, p<0.05] and on mRNA in the liver [F(3,15)=18.936,
p<0.01]. In line with our previous experiments, the saline-treated group exposed to the
conditioned stimulus on test day (Saline, white bars) exhibited significantly lower levels of
TNF-α mRNA and protein in the spleen and TNF-α mRNA in the liver (p<0.05) when
compared to the saline-treated home cage control group (Saline, black bars). In addition, the
raclopride treated group that was re-exposed to the conditioned stimulus on test day
(Raclopride, white bars) also exhibited a conditioned reduction in TNF-α mRNA and
protein in the spleen and mRNA in the liver as compared to the saline-treated control group
(p<0.05). TNF-α mRNA levels in the liver showed this same trend, however, ANOVA
revealed this was not statistically significant.
4. Discussion
The findings presented here demonstrate that dopamine within the basolateral amygdala
plays a critical role in the conditioned effects of heroin on proinflammatory mediators.
Specifically, these results revealed that antagonism of dopamine D1 receptors within the
BLA blocks the expression of heroin-induced conditioned suppression of nitric oxide, TNF-
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α and IL-1β. The SCH23390 compound has been used extensively as a selective D1
receptor antagonist and the dose of 2.0 µg/side was chosen based upon an established
literature showing an effect of this dose administered intra-BLA on cue-induced
reinstatement to drug seeking (Berglind et al., 2006; Alleweireldt et al., 2006). Interestingly,
selective antagonism of dopamine D2 receptors within this same region does not appear to
have any effect as the animals exposed to the conditioned stimulus and administered the
antagonist still exhibited a conditioned suppression in proinflammatory mediators.
Collectively, these data indicate a role for dopamine D1, but not D2, receptors in the
expression of heroin-induced conditioned immunomodulation. These data are in line with
similar studies demonstrating that intra-accumbens SCH23390 blocks the effects of opioid
drugs, and stimuli associated with opioid drugs, on NK cell activity and nitric oxide
production (Saurer et al., 2006; Saurer et al., 2009).
The mesolimbic dopamine system is known to be critically involved in the expression of the
rewarding properties of drugs of abuse, including opiates. In fact, heroin administration
indirectly induces increased dopamine by the binding of its metabolites to mu-opioid
receptors on GABA-ergic neurons within the ventral tegmental area. Dopamine has also
been widely implicated in the formation of memories underlying associative learning
processes. Specifically, dopamine and its receptors have been shown to mediate the learning
of associations between drugs of abuse and their conditioned cues and antagonism of
dopamine receptors may interfere with the acquisition or retrieval of reward-related
memories. For example, microdialysis studies revealed an increase in dopamine and its
metabolites during the learning of a discriminative task in rats (Hori et al., 1993) and upon
the presentation of a stimulus that had previously been paired with cocaine administration
(Weiss et al., 2000). In addition, intra-amygdalar 6-hydroxydopamine injections impaired
(Ashford & Jones, 1976), while post-training intra-BLA dopamine infusions enhanced
(LaLumiere et al., 2004) memory consolidation of a conditioned avoidance task.
Furthermore, intra-BLA infusions of amphetamine were found to potentiate cue-induced
drug-seeking behavior following extinction (Ledford et al., 2003). Taken together, these data
suggest a role for dopamine in the BLA in heroin-induced classically conditioned immune
alterations either through the mediation of neuroimmune pathways or indirectly through the
alteration of learning/memory processes.
The study of classical or Pavlovian conditioning allows for the dissociation of the
associative processes underlying the acquisition of a learned response from the mechanistic
control of the expression of the response itself. In many cases these two phenomena are
controlled via separate mechanisms. For example, antagonism of beta-adrenergic receptor
activity disrupts the expression but not the acquisition of conditioned morphine-induced
immune alterations (Coussons-Read et al., 1994). The data reported here suggest that
dopamine D1 receptors within the BLA are required for the expression of heroin’s
conditioned effects on proinflammatory mediators. However, it is unknown whether D1
receptors within the BLA might also be involved in the acquisition of these responses and
this presents an important area for future investigation. Interestingly, there appears to be
differential involvement of dopamine receptor subtypes within the BLA in the acquisition
and the expression of responses to conditioned drug cues. Several subtypes of dopamine
receptors have been characterized and the BLA has been shown to express both D1- and D2-
like receptors (Meador-Woodruff et al, 1991; Scibilia et al, 1992).Macedo et al. (2007)
demonstrated that antagonism of dopamine D1 receptors within the BLA reduces the
expression of conditioned, but not unconditioned, fear. In addition, stimulation of dopamine
D1 receptors in the BLA is necessary for the expression of cue-induced reinstatement of
cocaine-seeking behavior in rats (e.g., See et al., 2001; Yun & Fields, 2003). In contrast to
the role of D1 receptors, D2 receptors in the BLA appear to be involved in the acquisition of
associations between drugs and their cues. For example, blocking dopamine D2 receptors in
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the BLA during the acquisition phase of conditioning results in alterations in the
reinstatement of cue-induced cocaine-seeking behavior (Berglind et al., 2006). There has
also been evidence for the involvement of dopamine D3 receptors within the BLA in reward
learning as antagonism of these receptors was found to block reinstatement of drug seeking
under a second-order schedule of reinforcement (Di Ciano, 2008). Based on the evidence
from these studies it might also be important to examine the potential role of dopamine D2
and D3 receptors in the acquisition of associations between heroin and heroin-related cues
that elicit immunomodulation.
The BLA receives many of its dopaminergic inputs from the ventral tegmental area (VTA)
and substantia nigra as one of the main targets of the mesolimbic dopamine system
(Rosenkranz & Grace, 1999). These inputs appear to be important for learning to associate
the rewarding properties of drugs of abuse with external cues resulting in the ability of these
drug cues to induce relapse to drug-seeking and other conditioned behaviors (DiCiano &
Everitt, 2005; See, 2005). The data reported here suggest that opioids and opioid-associated
drug cues induce dopamine release from neurons originating in the VTA which then binds to
D1 receptors located within the BLA to influence the expression of conditioned responses to
heroin related cues. Research has shown that the primary targets of mesolimbic
dopaminergic neuron inputs to the BLA are the dendrites of the pyramidal neurons (Muller
et al., 2009). Within the BLA there exist two distinct neuronal cell populations, pyramidal
and non-pyramidal neurons. The pyramidal neurons of the BLA primarily utilize glutamate
as their neurotransmitter and exhibit spiny projections while the non-pyramidal cells rely
heavily upon inhibitory GABA signals and show fewer spines (McDonald, 1992). Dopamine
selectively increases the excitability of BLA pyramidal neurons allowing for potentiation of
the inputs from other brain regions, such as the cortex (Pickel et al., 2006). Interestingly, the
pyramidal cell glutamatergic projections from the BLA have been shown to synapse in close
proximity to dopamine axons on medium spiny neurons of the nucleus accumbens (Johnson
et al., 1994; Kelley et al., 1982; Robinson & Beart, 1988) thus giving rise to a complex
interaction between dopamine and glutamate within these two brain regions. In addition,
electrophysiological studies have shown that tetanic stimulation of the BLA evokes
dopamine efflux in the nucleus accumbens via glutamate receptor-dependent mechanisms
localized within the accumbens (Floresco et al., 1998). Furthermore, either exogenously
applied or synaptically released dopamine can modulate excitatory responses of nucleus
accumbens neurons evoked by low frequency stimulation of the BLA (Yim & Mogenson,
1982; 1986). Collectively, these data suggest that the circuit encompassing the VTA, BLA
and nucleus accumbens may be involved in the conditioned effects of heroin on immune
measures.
While it appears that the BLA does not directly impact immune functioning it is highly
plausible that conditioned immune alterations may be induced through the connections of
the BLA with the nucleus accumbens.Saurer et al. (2006a) demonstrated that intra-
accumbens shell administration of a dopamine D1 agonist resulted in decreased NK cell
activity indicating that dopamine activity within the accumbens is sufficient for expression
of heroin-induced conditioned immunomodulation. It is as yet unknown what factors may be
mediating these effects in the periphery but there is a wealth of data suggesting that the
sympathetic nervous system may be involved. For example, both primary and secondary
lymphoid tissues have been found to be innervated by the sympathetic nerve fibers
(Williams et al., 1981; Felten et al., 1984) and adrenergic receptors have been identified on
the surface of immune cells (Livnat et al., 1985; Hori et al., 1995; Maestroni, 2006). More
specifically, peripheral administration of β-adrenergic antagonists has been shown to block
the expression of the conditioned effects of morphine on several measurements of immune
status (Coussons-Read et al., 1994). However, it appears that at least some of these immune
alterations are mediated peripherally by neuropeptide Y as systemic administration of a
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neuropeptide Y Y1 receptor antagonist dose-dependently attenuates morphine-induced
alterations in NK cell activity while β-adrenergic antagonism had no effect (Saurer et al.,
2006b). These data seem to suggest differential mechanisms for the control of specific
opioid-induced immune alterations. It is imperative to understand the mechanisms by which
heroin-induced conditioned immunomodulation occurs as these effects may have
widespread implications for the health of recovering opiate users. Nitric oxide, TNF-α and
IL-1β are all components of the innate immune response that play critical roles in the host’s
initial response to pathogenic challenge. In the absence of a proper immune response, such
as occurs following exposure to drug-related cues, the host’s immune system may not be
able to adequately deal with infection. This disruption of immune functioning may allow for
increased pathogenic proliferation which may progress to sepsis. The exact neural
mechanism through which heroin-induced conditioned immunomodulation occurs is still not
fully understood, but the data presented here suggests that the BLA plays a critical role. The
experiments reported here are the first to identify the dopaminergic D1 receptors within the
BLA as crucial for the expression of the effects of heroin-related cues on immune
functioning.
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Effect of treatments on LPS-induced expression of iNOS mRNA in the spleen and liver as
determined by real-time RT-PCR. Exposure to the conditioned stimulus (Saline, white bar)
resulted in a conditioned suppression of iNOS mRNA in both the spleen and liver. Intra-
BLA microinfusion of the D1 receptor antagonist SCH23390 blocked the effect of the
conditioned stimulus (SCH23390, white bar). Data are expressed as iNOS copy number per
10 ng cDNA based on a standard curve using Roche LightCycler software.
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Effect of treatments on serum nitrite/nitrate levels as determined by the Greiss reagent assay.
Animals exposed to the conditioned stimulus on test day (Saline, white bar) exhibit a
conditioned suppression of serum nitrite/nitrate concentration. This suppression is blocked
by intra-BLA infusion of the dopamine D1 receptor antagonist SCH23390 (SCH23390,
white bar). The data are expressed as the micromolar concentration of nitrite/nitrate.
Szczytkowski and Lysle Page 16














Effect of treatments on LPS-induced expression of IL-1β mRNA and protein in the spleen
and liver as determined by real-time RT-PCR and ELISA. CS-exposed animals (Saline,
white bar) exhibit a conditioned suppression in both IL-1β mRNA and protein in both the
spleen and liver that is blocked by intra-BLA administration of the D1 receptor antagonist,
SCH23390 (SCH23390, white bar). mRNA data are expressed as IL-1β copy number per 10
ng cDNA based on a standard curve using Roche LightCycler software. ELISA data are
expressed as pg of cytokine protein per mg of total protein.
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Effect of treatment on LPS-induced expression of TNF-α mRNA and protein in the spleen
and liver as determined by real-time RT-PCR. Animals re-exposed to the CS on test day
(Saline, white bars) exhibited a conditioned suppression of TNF-α mRNA and protein that
was blocked by D1 receptor antagonism within the BLA (SCH23390, white bars). PCR data
are expressed as TNF-α copy number per 10 ng cDNA based on a standard curve using
Roche LightCycler software. ELISA data are expressed as pg of cytokine protein per mg of
total protein.
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Effect of treatments on LPS-induced expression of iNOS mRNA in the spleen and liver as
determined by real-time RT-PCR. CS exposure (Saline, white bars) significantly reduced
iNOS mRNA in both the spleen and liver and this effect was not blocked by intra-BLA D2
receptor antagonist administration (Raclopride, white bars). Data are expressed as iNOS
copy number per 10 ng cDNA based on a standard curve using Roche LightCycler software.
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Effect of treatments on serum nitrite/nitrate levels as determined by the Greiss reagent assay.
Exposure to the CS on test day resulted in a conditioned suppression of serum nitrite/nitrate
levels (Saline, white bar) that was not affected by intra-BLA raclopride (D2 antagonist)
administration (Raclopride, white bar). Data are expressed as the micromolar concentration
of nitrite/nitrate.
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Effect of treatments on LPS-induced expression of IL-1β mRNA in the spleen and liver as
determined by real-time RT-PCR and IL-1β protein levels as determined by ELISA.
Exposure to the CS on test day resulted in a suppression of IL-1b copy number and protein
levels in both the spleen and liver (Saline, white bars). Antagonism of dopamine D2
receptors within the BLA did not block this effect (Raclopride, white bars). PCR data are
expressed as IL-1β copy number per 10 ng cDNA based on a standard curve using Roche
LightCycler software. ELISA data are expressed as pg of cytokine protein per mg of total
protein.
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Effect of treatments on LPS-induced expression of TNF-α mRNA and protein in the spleen
and liver as determined by real-time RT-PCR. Animals re-exposed to the conditioned
stimulus (Saline, white bars) showed a conditioned suppression in TNF Effect of treatments
on LPS-induced expression of TNF-α mRNA and protein that was not altered by intra-BLA
raclopride treatment (Raclopride, white bars). The PCR data are expressed as TNF-α copy
number per 10 ng cDNA based on a standard curve using Roche LightCycler software.
ELISA data are expressed as pg of cytokine protein per mg of total protein.
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